4D Molecular
FDMT
4D Molecular (FDMT) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$1.01
- EPS estimate
- −$0.98
- EPS surprise
- −2.79%
- Revenue surprise
- −68.73%
- Revenue
- $90,000.00
- Revenue estimate
- $287,857.00
- Reported
- Nov 10, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$0.98 | −$1.01 | −2.79% | $90,000.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.73 | −$0.98 | −34.74% | $15,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.87 | −$0.86 | +1.24% | $14,000.00 | SEC |
| Q4 2024 | Feb 28, 2025 | −$0.84 | −$0.89 | −6.52% | $500.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.68 | −$0.79 | −16.88% | $3,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.68 | −$0.63 | +7.92% | $5,000.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.74 | −$0.66 | +10.92% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.61 | −$0.24 | +60.87% | $20.2M | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.78 | −$0.77 | +1.76% | $239,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.89 | −$0.88 | +1.49% | $298,000.00 | SEC |
| Q4 2022 | Mar 15, 2023 | −$0.79 | −$0.84 | −6.91% | $1.2M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.84 | −$0.79 | +6.40% | $500,000.00 | — |
| Q2 2022 | Aug 11, 2022 | −$0.85 | −$0.87 | −2.84% | $162,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$0.81 | −$0.82 | −0.92% | $1.2M | SEC |
| Q4 2021 | Mar 28, 2022 | −$0.85 | −$0.85 | +0.00% | $96,000.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.81 | −$0.82 | −1.23% | $1.4M | SEC |
| Q2 2021 | Aug 12, 2021 | −$0.68 | −$0.28 | +58.82% | $14.6M | SEC |
| Q1 2021 | May 13, 2021 | −$0.83 | −$0.53 | +36.14% | $2.0M | SEC |
Quarterly revenue
Frequently asked questions
When did 4D Molecular (FDMT) last report earnings?
4D Molecular last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did FDMT beat earnings estimates?
No. 4D Molecular reported EPS of −$1.01 for Q3 2025 against a −$0.98 estimate — a 2.79% miss.
How much revenue did FDMT report last quarter?
4D Molecular reported $90,000.00 in revenue for Q3 2025, against a consensus estimate of $287,857.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.